MARY1 is a selective 5-HT2BR antagonist with an IC50 of 380 nM and a Ki of 764 nM [human 5-HT2BR]. It promotes mitochondrial biogenesis (MB) in the kidneys and enhances mitochondrial function by increasing mitochondrial respiration capacity, protein levels, and number in renal proximal tubular cells (RPTC). MARY1 induces MB in RPTCs through the 5-HT2BR and dual PI3K/AKT and RAS/MEK/ERK signaling pathways. It is useful for studying kidney diseases related to metabolic and mitochondrial dysfunction.
Target:
5-HT Receptor|||Akt|||ERK|||MEK|||Ras|||PI3K
* VAT and and shipping costs not included. Errors and price changes excepted
